News
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=us)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: Biotest AG: Biotest treats first patient with severe community-acquired pneumonia in phase III trial with trimodulin
![Why CymaBay Therapeutics Stock Popped Again Today: https://g.foolcdn.com/editorial/images/747329/person-in-a-lab-looking-through-a-microscope.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMGlOYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--30fb2d43e418c179007f56079eaab02e50f919b2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/person-in-a-lab-looking-through-a-microscope.jpg?locale=us)
Why CymaBay Therapeutics Stock Popped Again Today
For the third day in a row, shares of CymaBay Therapeutics (NASDAQ: CBAY) enjoyed a very healthy gain in price. That came on the announcement of a capital-raising effort by the company. Ultimately
![VALBIOTIS SA: Valbiotis presents the full results of the Phase II/III REVERSE-IT study: impressive efficacy of TOTUM•63 against prediabetes and the early stages of type 2 diabetes: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNXFzSVE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--15bfdf03f8ab493929a3d2392e314697d3469f59/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/valbiotis-logo.jpg?locale=us)
VALBIOTIS SA: Valbiotis presents the full results of the Phase II/III REVERSE-IT study: impressive efficacy of TOTUM•63 against prediabetes and the early stages of type 2 diabetes
![Could This Issue Sink Johnson & Johnson's Stock Price?: https://g.foolcdn.com/editorial/images/746762/doctor-holding-elderly-patients-hand.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMTZNYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a5f219df633f7837f686b46ab8eb9b6845d9f13c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctor-holding-elderly-patients-hand.jpg?locale=us)
Could This Issue Sink Johnson & Johnson's Stock Price?
Pharmaceutical giant Johnson & Johnson (NYSE: JNJ) is no stranger to legal issues. The company is still dealing with a barrage of lawsuits alleging that its talc-based products gave customers
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=us)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
![2 Dirt Cheap Stocks to Buy With $100: https://g.foolcdn.com/editorial/images/747198/gettyimages-1191849990.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMlNNYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--caac2924b451a6130e5d6c414ffd69a246e20a0e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1191849990.jpg?locale=us)
2 Dirt Cheap Stocks to Buy With $100
We all love a good bargain, whether we're shopping for food, clothing -- or stocks. And even though the stock market has gained this year -- with the S&P 500 rising in the double digits -- there
![Cathie Wood Is Buying These 2 Biotech Stocks Hand Over Fist, and Wall Street Thinks They Could Double: https://g.foolcdn.com/editorial/images/746755/two-scientists-smile-at-lab-bench-while-holding-sample.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLzZMYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--170201fefadff63912beddde137cd31a8a754cf8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/two-scientists-smile-at-lab-bench-while-holding-sample.jpg?locale=us)
Cathie Wood Is Buying These 2 Biotech Stocks Hand Over Fist, and Wall Street Thinks They Could Double
Cathie Wood is known for her propensity to buy growth stocks that have the chance to disrupt their industries while also making early investors rich. And that means she's a big buyer of biotech
![Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy?: https://g.foolcdn.com/editorial/images/746822/a-young-scientist-recording-her-findings-on-a-tablet.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNVdMYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d5be88efbca58ce7c6c9023555acc258d3d2b75a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-young-scientist-recording-her-findings-on-a-tablet.jpg?locale=us)
Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy?
As you may have heard this summer, Biogen (NASDAQ: BIIB) is taking out a $1.5 billion-dollar loan to fund its acquisition of rare disease drug developer Reata Pharmaceuticals (NASDAQ: RETA) for $7.3
![3 Pharmaceutical Stocks That Are Too Cheap to Ignore: https://g.foolcdn.com/editorial/images/746850/healthcare-lab-treatment-research-scientist-1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNXVMYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--70fdcf8c9ddfaefba70afde94142596fe366ea21/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/healthcare-lab-treatment-research-scientist-1.jpg?locale=us)
3 Pharmaceutical Stocks That Are Too Cheap to Ignore
On average, healthcare stocks haven't kept up with the gains made by the rest of the market this year. While the S&P 500 index is up by more than 17% year to date, that sector's stocks are down by
![3 Unstoppable Growth Stocks to Buy Right Now: https://g.foolcdn.com/editorial/images/746929/smiling-man-holding-fist-up.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNFdMYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d63fce6da96a39fd4117c8b393e0ea9d48df9112/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/smiling-man-holding-fist-up.jpg?locale=us)
3 Unstoppable Growth Stocks to Buy Right Now
Sometimes, the laws of physics seem to apply to the stock market. That's especially the case when it comes to momentum. When certain stocks get a head of steam going, it's hard to slow them down.
![3 No-Brainer Dividend Stocks to Buy No Matter What the Market Is Doing: https://g.foolcdn.com/editorial/images/747029/gettyimages-586733088.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNFNMYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d5b468715532693fc89b0a99159d88865a0f79d4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-586733088.jpg?locale=us)
3 No-Brainer Dividend Stocks to Buy No Matter What the Market Is Doing
Certain stocks tend to perform better in a bull market, while others show their strengths in bear times. If you add both of these types of stocks to your portfolio, you're likely to benefit over the
![Why Shares of Insmed Are Soaring This Week: https://g.foolcdn.com/editorial/images/747060/radiologist-of-oncology-institute-is-examing-mri-scans.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMEtMYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--addd60d2129ebcf974d1488a43f6f5e069b146bf/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/radiologist-of-oncology-institute-is-examing-mri-scans.jpg?locale=us)
Why Shares of Insmed Are Soaring This Week
Shares of Insmed (NASDAQ: INSM) were up more than 17% for the week as of 10:30 a.m. ET on Friday, according to data provided by S&P Global Market Intelligence. The healthcare company closed last
![Why CymaBay Therapeutics Stock Is Jumping Today: https://g.foolcdn.com/editorial/images/747040/liver-doctor.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBelNMYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--95f7d7ab1797a20f8739c333c2fe8a795f6e5e86/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/liver-doctor.jpg?locale=us)
Why CymaBay Therapeutics Stock Is Jumping Today
Shares of CymaBay Therapeutics (NASDAQ: CBAY) were jumping 14.2% higher as of 10:54 a.m. ET on Friday. This move came on the heels of an 8.5% gain on Thursday.
The continued momentum is a result of
![1 Top Pharma Growth Stock to Buy Today and Hold Forever: https://g.foolcdn.com/editorial/images/746630/investor-thinks-while-looking-out-a-window.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeHlMYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7476bf8db540cbb2b5635bca0362e656f27116b6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-thinks-while-looking-out-a-window.jpg?locale=us)
1 Top Pharma Growth Stock to Buy Today and Hold Forever
If, like many other investors, you've written off big pharma stocks because of their reputation for being slow-growing giants, Vertex Pharmaceuticals (NASDAQ: VRTX) might be the breath of fresh air
![2 Top Biotech Stocks to Buy in September: https://g.foolcdn.com/editorial/images/746573/doctor-with-patient-talking.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdzJMYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--36de5dd9baa5b95ed1ba6cb94aad7f05a5bdd554/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctor-with-patient-talking.jpg?locale=us)
2 Top Biotech Stocks to Buy in September
September has historically been the worst month for the S&P 500, a phenomenon called the "September effect." The next few weeks may or may not live up (or down) to these low expectations, but
![Could These Be Vertex Pharmaceuticals' Most Promising Candidates?: https://g.foolcdn.com/editorial/images/746146/person-working-at-a-desk.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBKzZLYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--de8538ac9405b1f2be1813b40d851a46487c8cf7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/person-working-at-a-desk.jpg?locale=us)
Could These Be Vertex Pharmaceuticals' Most Promising Candidates?
Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) is firing on all cylinders. The company has performed better than the broader market in the past year as its core cystic fibrosis (CF) franchise
![Why Coherus BioSciences Stock Was Plunging This Week: https://g.foolcdn.com/editorial/images/747022/finger-about-to-press-the-delete-key-on-a-laptop-computer.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL09LYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--cffddad0368efb3e62a4a5c2fc6a04d8fbcfc040/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/finger-about-to-press-the-delete-key-on-a-laptop-computer.jpg?locale=us)
Why Coherus BioSciences Stock Was Plunging This Week
Live by the index, die by the index -- being included in a well-known collection of stocks can really help a company's visibility and boost investor morale. The opposite effect can kick in if it
![Wall Street Thinks This 7.6% Yielding Stock Has Up to 91% Upside. Should You Buy?: https://g.foolcdn.com/editorial/images/746430/person-sitting-on-the-couch-talking-on-a-cellphone.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOTJLYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fbb43eca84e1773d0902e508de3935e14863c449/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/person-sitting-on-the-couch-talking-on-a-cellphone.jpg?locale=us)
Wall Street Thinks This 7.6% Yielding Stock Has Up to 91% Upside. Should You Buy?
Most of the time, high-yielding stocks aren't coupled with high target prices from Wall Street. Instead, high yields usually convey market uncertainty, which is usually tied to a lower price target
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=us)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
![3 Dividend-Paying Tech Stocks to Buy Right Now: https://g.foolcdn.com/editorial/images/746721/happy-investor-drip-dividend-returns.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNm1LYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--91311be850ffd395a2af54ae202afa8573e7077a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/happy-investor-drip-dividend-returns.jpg?locale=us)
3 Dividend-Paying Tech Stocks to Buy Right Now
Over the past year, rising interest rates made dividend stocks a lot less appealing than fixed-income investments like CDs and bonds. They also broadly drove investors from tech stocks toward more
![African Nations are Pushing for the World's Top Polluters to Pay Up: https://g.foolcdn.com/editorial/images/746987/featured-daily-upside-image.jpeg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNGFLYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fa8f379d1f87faa011470f87253bc0670940aa5a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-daily-upside-image.jpg?locale=us)
African Nations are Pushing for the World's Top Polluters to Pay Up
For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.
Climate change
![Could Pfizer Stock Help You Become A Millionaire?: https://g.foolcdn.com/editorial/images/746532/a-rich-person-counting-money.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOUtKYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4f8f4d8f827675646208f37c0b26060e9543a508/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-rich-person-counting-money.jpg?locale=us)
Could Pfizer Stock Help You Become A Millionaire?
For any investment, getting it to $1 million can be a lofty goal to set. It's by no means an easy task, and will require a sizable buy-in, lots of patience, and good returns along the way. Below
![3 Dividend Stocks That Could Be Ideal Buys for Retirees in September: https://g.foolcdn.com/editorial/images/746386/a-couple-reviewing-a-statement.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBenlKYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4925f19bec52404402d6cffb0616fa9c23292714/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-couple-reviewing-a-statement.jpg?locale=us)
3 Dividend Stocks That Could Be Ideal Buys for Retirees in September
Inflation is making life harder for everyone, including retirees who need to stretch out their savings to help cover additional costs. One way to help offset rising inflation is to invest in
![3 Things About AT&T That Smart Investors Know: https://g.foolcdn.com/editorial/images/746433/gettyimages-1304102571.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMEtKYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0f21de4f59099c946bec25d4ba020964fae6632b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1304102571.jpg?locale=us)
3 Things About AT&T That Smart Investors Know
If you've been an AT&T (NYSE: T) shareholder for some years now, I'm sure I don't have to tell you how turbulent a ride it has been. The telecom giant is down by more than 34% in the past three